New pill shows promise for Hard-to-Treat ovarian cancer
NCT ID NCT07652073
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new oral drug called DAT-2645 in up to 30 people with advanced or metastatic ovarian cancer that has a BRCA1/2 mutation or is HRD-positive. Participants take the drug daily in 21-day cycles. The main goal is to see if the drug shrinks tumors, and researchers will also monitor safety and how long any benefit lasts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DAT-2645 tablet
- What this could lead to
- If successful, this could provide a new oral treatment option for advanced ovarian cancer patients with specific genetic mutations who have run out of standard therapies.
- What could go wrong
- This is an early Phase 2 trial with only 30 participants, so results may not apply to everyone. The drug may not shrink tumors or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Research site
Guangzhou, Guangdong, 510050, China
-
Research site
Beijing, 100021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.